Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.670 +0.040 (+0.60%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Insiders Selling DocuSign, Adobe And 2 Other Stocks ↗

January 24, 2023

The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock ↗

January 18, 2023

Via Benzinga

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

January 05, 2023

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook ↗

November 01, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Myriad Genetics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

December 30, 2022

Friday's session saw 75 companies set new 52-week lows.

Via Benzinga

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

December 19, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

December 08, 2022

Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

November 29, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

November 17, 2022

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

November 14, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

November 10, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Why Shares of Myriad Genetics Dropped 24% This Week ↗

November 03, 2022

The genetic-testing company announced an acquisition and lowered its guidance.

Via The Motley Fool

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

November 03, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday ↗

November 02, 2022

Gainers

Via Benzinga

Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast ↗

November 01, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 01, 2022

Gainers

Via Benzinga

Dow Drops Over 200 Points; Crude Oil Rises Sharply ↗

November 01, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 01, 2022

On Tuesday, 85 stocks hit new 52-week lows.

Via Benzinga

Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session ↗

November 01, 2022

Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.

Via Benzinga

Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday ↗

November 01, 2022

U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Myriad Genetics: Q3 Earnings Insights ↗

November 01, 2022

Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement.

Via Benzinga

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

November 01, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Reports Third Quarter Financial Results

November 01, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

October 31, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 1, 2022 ↗

November 01, 2022

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.

Via Benzinga

Earnings Preview: Myriad Genetics ↗

October 31, 2022

Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad...

Via Benzinga

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

October 26, 2022

From Myriad Genetics, Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.